Longport PP&E per Employee
The PP&E per Employee of Longport (LPTI) as of Aug 15, 2026 is 30,024.13 USD.
Get this data via API
Financial Data API
PP&E per Employee
30,024.13USD
Last updated:
PP&E per Employee of Longport is 2026 30,024.13 USD. PP&E per Employee of Longport was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Longport Stock analysis
What does Longport do? Longport Inc is a US-based company specializing in the development, manufacturing, and marketing of medical devices. It was founded in 1998 by a group of engineers and businesspeople with a vision to create devices that make medical treatments more effective and safer.
The business model of Longport Inc is based on providing customized solutions for medical applications. The company offers a wide range of products and services focusing on various medical fields such as radiology, urology, neurology, gastroenterology, and cardiology. Another focus is on developing products for the treatment of vascular diseases.
The company follows a customer-oriented philosophy tailored to the needs of its customers. It works closely with hospitals and other healthcare facilities and has built partnerships with medical device companies worldwide.
Longport Inc is headquartered in New Jersey, USA, and has branches in Europe and Asia. It employs a wide range of professionals including engineers, scientists, salespeople, and managers.
In terms of its various product divisions, Longport Inc is best known for its medical imaging products. The company has developed a range of products that contribute to improving the accuracy and effectiveness of X-ray and ultrasound images. These include image processing software, detectors, and other accessories.
In urology, Longport Inc has developed a wide range of products supporting the diagnosis and treatment of prostate diseases. This includes devices such as the transrectal ultrasound probe and the prostate biopsy needle.
In neurology, the company offers devices for the diagnosis and treatment of brain injuries and diseases. These range from stereotactic devices used for deep brain stimulation procedures to devices used for measuring brain waves.
In the field of gastroenterology, Longport Inc provides products for the diagnosis and treatment of gastrointestinal inflammation, as well as for the treatment of stomach ulcers and other stomach issues.
Finally, the company also develops products for other medical applications beyond its core areas. These include devices for monitoring blood pressure, measuring blood glucose levels, and treating heart diseases.
Over the years, Longport Inc has received several awards for its innovative products and exceptional achievements in the field of medical device manufacturing. The company is committed to continuing to develop innovative solutions for the medical industry to improve patient treatment worldwide. Longport is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Longport stock
PP&E per Employee of Longport is 30,024.13 USD in 2026.
On Eulerpool you can find the complete historical development of PP&E per Employee Longport since 2006 – with annual values, charts, and detailed analysis.
PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.
PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Longport historically and in real time.
Access this data via the Eulerpool API
Workforce — Longport
All Key Metrics — Longport
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth